

Presentation and CEO's address to the 2023 Extraordinary General Meeting

14 June 2023

4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) attaches the following materials to be presented at the Extraordinary General Meeting of Shareholders to be held today at 11.30am AEST:

1. Script of the prepared address to be given by the Managing Director and CEO; and
2. Presentation slides to accompany the meeting.

The Chair, Mr Bruce Rathie, will preside over the meeting but will not deliver an address.

–ENDS–

Authorised by the 4DMedical Company Secretary.

Contacts

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 102
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



4DMedical Limited
Extraordinary General Meeting
Managing Director and CEO's address
11.30AM, Wednesday 14 June 2023

Good morning ladies and gentlemen,

I am excited to be here with you today following our recent successes in capital raising, resulting in a significant expression of confidence in 4DMedical by both institutional and retail investors.

This confidence reflects the Company's recent achievements with the US Veterans Affairs and Department of Defense, and the signing of a five-year commercial contract with the University of Miami. In addition, we are also excited with the Australian release of our new product, Computed Tomography-enabled ventilation (CT:V), and the development of its extension into perfusion (CT:VQ).

Translating our technology into better outcomes for lung health is only possible with the sustained confidence of investors. Our \$20 million Placement to institutional and professional investors during May was completed multiple times oversubscribed, and included the addition of several new institutional investors to the company register.

Recognising the continuous commitment of retail investors to 4DMedical, the Company made specific provision for existing shareholders to participate in our capital raise through a Securities Purchase Plan (SPP). We were delighted with the strong demand, which surpassed the objective of a minimum of \$15 million, with total funds raised under the SPP of \$25 million.

The SPP and Placement combined raised \$45 million (before costs) and will be used to accelerate commercialisation of the Company's respiratory imaging product lines and significantly strengthen the Company's balance sheet – ultimately providing assurance to the many doctors and patients that may benefit from the end-use of our transformative technology.

To ensure the attaching options can now be issued to investors who participated in the Placement and SPP, the Board seeks approval for the resolutions put before this meeting today.


On behalf of the Board of 4DMedical I thank you for your interest and involvement, and kindly seek your approval today.



The future of lung health

4D Medical Limited (ASX:4DX)

Extraordinary General Meeting
14 June 2023 11:30am



This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (**Company** or **4DMedical**). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (**Group**) and their activities current as of 14 June 2023 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities.

This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian *Corporations Act 2001* (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase securities and does not include any application form for securities. This presentation does not constitute an advertisement for an offer or proposed offer of securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this presentation may not be distributed or released in the United States. The securities in the Company (**Securities**) have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Securities may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States.

1. Opening & introductions
2. CEO address
3. Procedural matters
4. Formal business
5. Closing remarks

Chairman's introduction



BRUCE RATHIE
Non-Executive Chairman

Experienced lawyer, investment banker and company director.

Board of directors

The Board has the right mix of medical and commercial sector experience



BRUCE RATHIE
Non-Executive Chairman

Experienced lawyer, Investment Banker and Company Director; currently Non-Executive Director of PolyNovo Limited (PNV.ASX) and Cettire Limited (CTT.ASX), and Chairman of Cleanspace Holdings Limited (ASX:CSX)



Dr ANDREAS FOURAS PhD
Managing Director and Chief Executive Officer

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.



LIL BIANCHI
Non-Executive Director; Chair, Audit & Risk Committee

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.



Dr ROBERT A. FIGLIN MD
Non-Executive Director

Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai.



JULIAN SUTTON
Non-Executive Director

Chartered Financial Analyst who began his career as an actuarial analyst in Melbourne before moving into funds management with Schroders and Credit Suisse in London.



JOHN LIVINGSTON
Executive Director

Founding partner of ASX listed Integral Diagnostics (IDX.ASX) and an industry leader in the implementation of PACS and RIS in radiological settings.



EVONNE COLLIER
Non-Executive Director; Chair, Remuneration & Nomination Committee

Experienced in board appointments (ASX, private, publicly unlisted) with executive background in marketing, innovation/tech and commercial roles; currently Non-Executive Director of SaaS analytics company, Sage Automation.

Key Advisors



Dr SAM HUPERT MBBS
Advisory Board Member

Co-founder and Chief Executive Officer of Pro Medicus Ltd (PME.ASX) which develops and markets health imaging software primarily for radiologists in the U.S., Europe and Australia.



Prof BRUCE THOMPSON PhD
Advisory Board Member

Board Member and Past President of the Thoracic Society of Australia and New Zealand; currently Dean of the School of Health Sciences at the University of Melbourne, and a former Head of Physiology Services at the Alfred Hospital.



Dr DAVID J. SHULKIN, M.D.
Key Advisor

Highly respected physician and health care executive, Dr Shulkin was previously the Secretary of the United States Department of Veterans Affairs (VA). As Secretary of the VA, Dr Shulkin oversaw the US government's second largest agency, with over 350,000 employees and 1,700 facilities, serving over 9 million Veterans.


Chief Executive Officer




Dr ANDREAS FOURAS PhD
Managing Director

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.

Procedural matters



Formal business



- Resolution 1: Ratification of issue of Shares under the Offers.
- Resolution 2: Approval of proposed issue of New Options under the Offers.

Item 1. Ratification of issue of Shares under the Offers.

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, in accordance with Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue by the Company of Shares under the Offers, on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain/Exclude
78,562,460	408,252	1,027,687	5,739,530
98.21%	0.51%	1.28%	

Further Information

- The Board unanimously recommends that Shareholders vote in favour of Resolution 1.
- The Chair of the meeting intends to vote undirected proxies in favour of the Resolution.
- Voting restrictions apply to participants in the recent Placement and Securities Purchase Plan.

Item 2. Approval of proposed issue of New Options under the Offers.

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:


“That, in accordance with Listing Rule 7.1 and for all other purposes, Shareholders approve the proposed issue by the Company of New Options under the Offers, on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain/Exclude
79,309,036	469,042	1,027,687	5,684,585
98.15%	0.58%	1.27%	

Further Information

- The Board unanimously recommends that Shareholders vote in favour of Resolution 2.
- The Chair of the meeting intends to vote undirected proxies in favour of the Resolution.
- Voting restrictions apply to participants in the recent Placement and Securities Purchase Plan.

Poll





The Future of Lung Health

4D Medical Limited (4DX)

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au